Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808870 | 1.00 | CTSS (0.44) | CTSSCTSKKCNQ4KCNQ5EGLN2 | |
| SCHEMBL25751479 | 0.83 | CYP4F2 (0.44) | CTSSCTSKKCNQ4KCNQ5EGLN2 | |
| SCHEMBL30300988 | 0.83 | KMT2A (0.41) | CTSSCTSKEGLN2CYP17A1TOP2A | |
| SCHEMBL28860305 | 0.81 | CA12 (0.43) | KCNQ4KCNQ5EGLN2CYP17A1RORC | |
| SCHEMBL1368399 | 0.80 | AURKA (0.47) | CTSSCTSKCYP17A1CTSLCTSB | |
| SCHEMBL1368433 | 0.79 | CYP17A1 (0.56) | CTSSCTSKCYP17A1NR1H2 | |
| SCHEMBL26690204 | 0.79 | KMT2A (0.39) | — | |
| SCHEMBL24816283 | 0.75 | LCK (0.41) | EGLN2CYP17A1RORC | |
| SCHEMBL31457043 | 0.75 | LCK (0.41) | EGLN2CYP17A1RORC | |
| SCHEMBL4895564 | 0.75 | GRM4 (0.45) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023027966-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | CTSS 1153/4885CTSK 994/4885KCNQ4 4660/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | CTSS 1949/4885CTSK 1464/4885KCNQ4 4638/4885 |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | FLT3, MCL1, JAK2 | CTSS 1173/4885CTSK 999/4885KCNQ4 4601/4885 |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | CTSS 1153/4885CTSK 994/4885KCNQ4 4660/4885 |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | FLT3, MEN1, FEM1B | CTSS 2248/4885CTSK 2364/4885KCNQ4 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.